β3-Adrenoceptors: A drug target in ophthalmology?

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 4, 2013, Pages 265-267

  Gericke, Adrian ^a   Böhmer, Tobias ^a   Michel, Martin C ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; CL 316 243; CYCLIC AMP; CYCLIC GMP; L 748337; PROPRANOLOL; SR 59230 A; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CILIARY MUSCLE; DRUG SELECTIVITY; DRUG TARGETING; EXCITOTOXICITY; IMMUNOHISTOCHEMISTRY; NONHUMAN; OBESITY; OXYGEN SUPPLY; PROTEIN EXPRESSION; RETINA; RETINA ARTERY OCCLUSION; RETINA INJURY; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; REVIEW; SPHINCTER PUPILLAE MUSCLE; SQUAMOUS EPITHELIUM; VASODILATATION;

ANIMALS; RECEPTORS, ADRENERGIC, BETA-3; RETINA;

EID: 84876408004     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0835-6     Document Type: Review

References (27)

1. Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S (1984) Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309:163-165
2. Baker JG (2005) The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 144:317-322
3. Bloom JD, Dutia MD, Johnson BD, Wissner A, Burns MG, Largis EE, Dolan JA, Claus TH (1992) Disodium (R, R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]- amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent. J Med Chem 35:3081-3084
4. 3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 385:875-882
5. Chen J, Joyal JS, Hatton CJ, Juan AM, Pei DT, Hurst CG, Xu D, Stahl A, Hellstrom A, Smith LE (2012) Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 53:2968-2977
6. Dal Monte M, Martini D, Ristori C, Azara D, Armani C, Balbarini A, Bagnoli P (2011) Hypoxia effects on proangiogenic factors in human umbilical vein endothelial cells: functional role of the peptide somatostatin. Naunyn Schmiedebergs Arch Pharmacol 383:593-612
7. Dal Monte M, Latina V, Cupisti E, Bagnoli P (2012a) Protective role of somatostatin receptor 2 against retinal degeneration in response to hypoxia. Naunyn Schmiedebergs Arch Pharmacol 385:481-494
8. Dal Monte M, Martini D, Latina V, Pavan B, Filippi L, Bagnoli P (2012b) Beta-adrenoreceptor agonism influences retinal responses to hypoxia in a model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 53:2181-2192
9. 3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants. Naunyn-Schmiedeberg's Arch Pharmacol. doi: 10.1007./s00210-012-0828-x
10. Diebold Y, Rios JD, Hodges RR, Rawe I, Dartt DA (2001) Presence of nerves and their receptors in mouse and human conjunctival goblet cells. Invest Ophthalmol Vis Sci 42:2270-2282
11. Enriquez de Salamanca A, Siemasko KF, Diebold Y, Calonge M, Gao J, Juarez-Campo M, Stern ME (2005) Expression of muscarinic and adrenergic receptors in normal human conjunctival epithelium. Invest Ophthalmol Vis Sci 46:504-513
12. Evans BA, Sato M, Sarwar M, Hutchinson DS, Summers RJ (2010) Ligand-directed signalling at beta-adrenoceptors. Br J Pharmacol 159:1022-1038
13. 3-adrenergic relaxation of bovine iris sphincter. FEBS Lett 429:356-358
14. 3- adrenoceptor agonists, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 63(2):283-295
15. 3-adrenoceptor agonists: implications for the selection of drug development candidates. Eur J Pharmacol 657:1-3
16. 3-adrenoceptors in rat retinal blood vessels. Naunyn Schmiedebergs Arch Pharmacol 382:119-126
17. 3-adrenoceptors in regulation of retinal vascular tone in rats. Naunyn Schmiedebergs Arch Pharmacol 384:603-608
18. 3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 62:834-840
19. 3-adrenoceptor agonist CL316243 against N-methyl-d-aspartate-induced retinal neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol 385:1077-1081
20. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 92:905-909
21. Pierce EA, Foley ED, Smith LE (1996) Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 114:1219-1228
22. Pradidarcheep W, Stallen J, Labruyere WT, Dabhoiwala NF, Michel MC, Lamers WH (2009) Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379:397-402
23. Ristori C, Filippi L, Dal Monte M, Martini D, Cammalleri M, Fortunato P, la Marca G, Fiorini P, Bagnoli P (2011) Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci 52:155-170
24. Shen Y, Liu XL, Yang XL (2006) N-methyl-d-aspartate receptors in the retina. Mol Neurobiol 34:163-179
25. 3-adrenergic receptors regulate retinal endothelial cell migration and proliferation. J Biol Chem 278:20681-20686
26. 3-adrenergic receptors mediate choroidal endothelial cell invasion, proliferation, and cell elongation. Exp Eye Res 80:83-91
27. Topalkara A, Karadas B, Toker MI, Kaya T, Durmus N, Turgut B (2006) Relaxant effects of beta-adrenoceptor agonist formoterol and BRL 37344 on bovine iris sphincter and ciliary muscle. Eur J Pharmacol 548:144-149